Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-30
2011-08-30
Seaman, D (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S414000, C546S113000, C548S465000
Reexamination Certificate
active
08008320
ABSTRACT:
The present invention relates to a compound of formula (I) wherein R1is H, C1-C6-alkyl, phenyl-C1-C4-alkyl or phenyl, R2is a phenyl group which is substituted with 2 or 3 C1-C6-alkoxy groups and R3is indolyl or azaindolyl which may carry one or two substituents independently selected from C1-C6-alkyl, C1-C6-alkoxy, phenyl, OH, halogen, NH2, C1-C6-alkylamino, di-C1-C6-alkylamino, heteroaryl with 5 or 6 ring atoms containing 1 or 2 heteroatoms which are independently selected from O, N, and S and heterocyclyl with 5 or 6 ring atoms containing 1 or 2 heteroatoms which are independently selected from O, N, and S and the physiologically acceptable salts thereof as well as the physiologically acceptable solvates of the compounds of formula 1 and of the salts thereof. The compounds of formula (I) are suitable for controlling angiogenesis.
REFERENCES:
patent: 5057614 (1991-10-01), Davis et al.
patent: 7001906 (2006-02-01), Prudhomme et al.
patent: 2004/0054180 (2004-03-01), Zhang et al.
patent: 2004/0192718 (2004-09-01), Zhang et al.
patent: 2010636 (1990-08-01), None
patent: 0540956 (1993-05-01), None
patent: 1224932 (2002-07-01), None
patent: WO 91/13071 (1991-09-01), None
patent: WO 95/07910 (1995-03-01), None
patent: WO 97/34890 (1997-09-01), None
patent: WO 00/21927 (2000-04-01), None
patent: WO 00/38675 (2000-07-01), None
patent: WO 02/10158 (2002-02-01), None
patent: WO 02/38561 (2002-05-01), None
patent: 03002563 (2003-01-01), None
patent: WO 03/057202 (2003-07-01), None
patent: WO 03/095452 (2003-11-01), None
patent: WO 03/103663 (2003-12-01), None
patent: WO 2006/061212 (2006-06-01), None
International Search Report for International Application No. PCT/EP2005/013126 (2006).
International Preliminary Report on Patentability for International Application No. PCT/EP2005/013126 (2006).
Zhang et al., “3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase Kinase-3”,Bioorganic&Medicinal Chemistry Letters, 14(12), 3245-3250 (2004).
Bokhari et al., “Regulation of Skin Microvasculature Angiogenesis, Cell Migration, and Permeability by a Specific Inhibitor of PKCα”,J. Invest. Dermatol., 2006, 126 (2), 460-467.
Cabebe et al., “Sunitinib: A newly approved small-molecule inhibitor of angiogenesis”,Drugs of Today, 2006, 42 (6), 387-398.
Davis et al., “Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides”,J. Med. Chem., 1992, 35, 177-184.
Davis et al., “Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity”,J. Med. Chem., 1992, 35, 994-1001.
Faul et al., “Cyclization strategies for the synthesis of macrocyclic bisindolylmaleimides”,J. Org. Chem., 2001, 66, 2024-2033.
Faul et al., “Acyclic N-(azacycloalkyl)bisindolylmaleimides: Isozyme selective inhibitors of PKCβ”,Bioorg. Med. Chem. Lett., 2003, 13, 1857-1859.
Faul et al., “A New, Efficient Method for the Synthesis of Bisindolylmaleimides”,J. Org. Chem., 1998, 63, 6053-6058.
Faul et al., “A New One Step Synthesis of Maleimides by Condensation of Glyoxylate Esters with Acetamides”,Tetrahedron Letters, 1999, 40, 1109-1112.
Hands et al., “A Convenient Method for the Preparation of 5-, 6- and 7-Azaindoles and Their Derivatives”,Synthesis, 1996, 7, 877-882.
Mahadevan et al., “Synthesis of Pyrrolopyridines (Azaindoles)”,J. Heterocycl. Chem., 1992, 29, 359-367.
Okauchi et al. , “A General Method for Acylation of Indoles at the 3-Position with Acyl Chlorides in the Presence of Dialkylaluminum Chloride”,Organic Letters, 2000, 2 (10), 1485-1487.
O'Neill et al., “Design, synthesis and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3β (GSK-3β) inhibitors”,Bioorg. Med. Chem., 2004, 12, 3167-3185.
Peifer et al., “Profile and Molecular Modeling of 3-(Indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1 H-pyrrole-2,5-dione (1) as a Highly Selective VEGF-R2/3 Inhibitor”,J. Med. Chem., 2006, 49, 7549-7553.
Peifer et al., “Design, Synthesis, and Biological Evaluation of 3,4-Diarylmaleimides as Angiogenesis Inhibitors”,J. Med. Chem., 2006, 49, 1271-1281.
Peifer et al., “A novel quantitative chick embryo assay as an angiogenesis model using digital image analysis”,Anticancer Res., 2004, 24, 1545-1552.
Tanaka et al., “Synthesis of anilino-monoindolylmaleimides as potent and selective PKCβ inhibitors”,Bioorganic&Medicinal Chem. Lett., 2004,14, 5171-5174.
Tholander et al., “Syntheses of 6,12-Disubstituted 5,11-Dihydroindolo[3,2-b]carbazoles, Including 5,11-Dihydroindolo[3,2-b]carbazole-6,12-dicarbaldehyde, an Extremely Efficient Ligand for the TCDD (Ah) Receptor”,Tetrahedron1999, 55 (43), 12577-12594.
Xu et al., “Synthesis and cytotoxicity of indolopyrrolemaleimides”,Chem. Pharm. Bull. (Tokyo), 2007, 55, 1302-1307.
Zhang et al., “A General Method for the Preparation 4- and 6-Azaindoles”,J. Org. Chem., 2002, 67, 2345-2347.
Zhang et al., “An Effective Procedure for the Acylation of Azaindoles at C-3”,J. Org. Chem., 2002, 67, 6226-6227.
Zhang et al., “Novel indolylindazolylmaleimides as inhibitors of protein kinase C-β: synthesis, biological activity, and cardiovascular safety”,J. Med. Chem., 2005, 48, 1725-1728.
Dannhardt Gerd
Kramb Jan-Peter
Peifer Christian
Plutizki Stanislav
Johannes Gutenberg-Universitatis
Rahmani Niloofar
Seaman D
Viksnins Harris & Padys PLLP
LandOfFree
3-(indolyl)-4-arylmaleimide derivatives and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-(indolyl)-4-arylmaleimide derivatives and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-(indolyl)-4-arylmaleimide derivatives and their use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2684441